Literature DB >> 18301057

Increased detection of HIV-specific T cell responses by combination of central sequences with comparable immunogenicity.

Nicole Frahm1, David C Nickle, Caitlyn H Linde, Daniel E Cohen, Rosario Zuñiga, Aldo Lucchetti, Timothy Roach, Bruce D Walker, Todd M Allen, Bette T Korber, James I Mullins, Christian Brander.   

Abstract

OBJECTIVE: To evaluate the recognition of computationally designed, centralized HIV-1 antigens derived from clade B, C and group M sequences by individuals infected with HIV-1-M clades B and C.
METHODS: Three centralized sequences have been described - consensus, ancestor and center-of-tree - each of which attempts to minimize the genetic distance to circulating viruses. It is unclear whether any of these sequences affords an advantage for T cell recognition. The ability of centralized clade B and C and group M peptides to be targeted in ELISpot assays was assessed using samples from the United States, Peru, Barbados and South Africa.
RESULTS: Each of the clade-specific centralized peptide sets was equally powerful in detecting cytotoxic T cell (CTL) responses. Importantly, combination of these sets detected significantly broader responses. Although broad responses were observed in populations from which few sequences informed the design of these centralized sequences, the genetic distance between local sequences and the respective test set was inversely associated with response rates. Furthermore, the CTL reactivity in clade C-infected subjects using clade B peptides was reduced relative to within-clade peptide responses, while responses to group M peptides were comparable to within-clade peptide responses in these individuals.
CONCLUSIONS: All tested centralized antigens provided a similarly potent set of antigenic peptides. However, the significantly broader responses detected using the combination of sets highlight the importance of maximizing coverage of HIV-1 sequence diversity in vaccine preparations, as well as in the evaluation of CTL responses in HIV-1-infected individuals and those vaccinated.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18301057     DOI: 10.1097/QAD.0b013e3282f42412

Source DB:  PubMed          Journal:  AIDS        ISSN: 0269-9370            Impact factor:   4.177


  20 in total

Review 1.  T-cell vaccine strategies for human immunodeficiency virus, the virus with a thousand faces.

Authors:  Bette T Korber; Norman L Letvin; Barton F Haynes
Journal:  J Virol       Date:  2009-05-13       Impact factor: 5.103

2.  Performance of a redesigned HIV Selectest enzyme-linked immunosorbent assay optimized to minimize vaccine-induced seropositivity in HIV vaccine trial participants.

Authors:  Oksana Penezina; Neil X Krueger; Isaac R Rodriguez-Chavez; Michael P Busch; John Hural; Jerome H Kim; Robert J O'Connell; Eric Hunter; Said Aboud; Keith Higgins; Victor Kovalenko; David Clapham; David Crane; Andrew E Levin
Journal:  Clin Vaccine Immunol       Date:  2014-01-08

3.  Mosaic HIV-1 Gag antigens can be processed and presented to human HIV-specific CD8+ T cells.

Authors:  Zaza M Ndhlovu; Alicja Piechocka-Trocha; Seanna Vine; Ashley McMullen; Kegakilwe C Koofhethile; Phillip J R Goulder; Thumbi Ndung'u; Dan H Barouch; Bruce D Walker
Journal:  J Immunol       Date:  2011-05-16       Impact factor: 5.422

4.  Exploiting knowledge of immune selection in HIV-1 to detect HIV-specific CD8 T-cell responses.

Authors:  Coral-Ann M Almeida; Steven G Roberts; Rebecca Laird; Elizabeth McKinnon; Imran Ahmad; Niamh M Keane; Abha Chopra; Carl Kadie; David Heckerman; Simon Mallal; Mina John
Journal:  Vaccine       Date:  2010-07-07       Impact factor: 3.641

Review 5.  HIV-1 vaccine development after STEP.

Authors:  Dan H Barouch; Bette Korber
Journal:  Annu Rev Med       Date:  2010       Impact factor: 13.739

6.  Expanded breadth of the T-cell response to mosaic human immunodeficiency virus type 1 envelope DNA vaccination.

Authors:  Wing-Pui Kong; Lan Wu; Timothy C Wallstrom; Will Fischer; Zhi-Yong Yang; Sung-Youl Ko; Norman L Letvin; Barton F Haynes; Beatrice H Hahn; Bette Korber; Gary J Nabel
Journal:  J Virol       Date:  2008-12-24       Impact factor: 5.103

7.  HLA class I-driven evolution of human immunodeficiency virus type 1 subtype c proteome: immune escape and viral load.

Authors:  Christine M Rousseau; Marcus G Daniels; Jonathan M Carlson; Carl Kadie; Hayley Crawford; Andrew Prendergast; Philippa Matthews; Rebecca Payne; Morgane Rolland; Dana N Raugi; Brandon S Maust; Gerald H Learn; David C Nickle; Hoosen Coovadia; Thumbi Ndung'u; Nicole Frahm; Christian Brander; Bruce D Walker; Philip J R Goulder; Tanmoy Bhattacharya; David E Heckerman; Bette T Korber; James I Mullins
Journal:  J Virol       Date:  2008-04-23       Impact factor: 5.103

8.  Design, expression, and processing of epitomized hepatitis C virus-encoded CTL epitopes.

Authors:  Daniel Yerly; David Heckerman; Todd Allen; Todd J Suscovich; Nebojsa Jojic; Carl Kadie; Werner J Pichler; Andreas Cerny; Christian Brander
Journal:  J Immunol       Date:  2008-11-01       Impact factor: 5.422

9.  Alternative effector-function profiling identifies broad HIV-specific T-cell responses in highly HIV-exposed individuals who remain uninfected.

Authors:  Marta Ruiz-Riol; Anuska Llano; Javier Ibarrondo; Jennifer Zamarreño; Karina Yusim; Vanessa Bach; Beatriz Mothe; Susana Perez-Alvarez; Marco A Fernandez; Gerard Requena; Michael Meulbroek; Ferran Pujol; Agathe Leon; Patricia Cobarsi; Bette T Korber; Bonaventura Clotet; Carmela Ganoza; Jorge Sanchez; Josep Coll; Christian Brander
Journal:  J Infect Dis       Date:  2014-09-23       Impact factor: 5.226

10.  Functional properties and epitope characteristics of T-cells recognizing natural HIV-1 variants.

Authors:  U Malhotra; J Nolin; H Horton; F Li; L Corey; J I Mullins; M J McElrath
Journal:  Vaccine       Date:  2009-09-09       Impact factor: 3.641

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.